PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with tricuspid bioprosthetic structural valve degeneration (SVD) often present with right ventricular enlargement and severe dysfunction, which cause a higher risk for redo cardiac surgery. In 2019, our center innovated using the J-valve system for valve-in-valve (ViV) implantation to treat tricuspid bioprosthetic SVD. The purpose of this study was to summarize the clinical effect after 1-year follow-up.
UNASSIGNED: From April 2019 to October 2019, two cases of tricuspid bioprosthetic dysfunction were treated with the J-valve system. Both patients were male, aged 46 and 67 years, respectively. The preoperative evaluation showed that the risk of conventional redo open heart surgery was high. The J-valve implantation was successful in both cases. One patient had slight valve displacement when the transporter was withdrawn during the operation, and a second J-valve was implanted in an ideal position. There was no death, no delayed valve displacement, and no readmission during the follow-up period of 12 months. In both cases, there was an absence of trace tricuspid regurgitation. After 6 months of anticoagulation with warfarin, the patients were converted to long-term aspirin treatment.
UNASSIGNED: The ViV technique with J-valve is feasible and effective in treating tricuspid bioprosthetic SVD in high-risk patients, avoiding cardiopulmonary bypass and conventional thoracotomy injury.
UNASSIGNED: From April 2019 to October 2019, two cases of tricuspid bioprosthetic dysfunction were treated with the J-valve system. Both patients were male, aged 46 and 67 years, respectively. The preoperative evaluation showed that the risk of conventional redo open heart surgery was high. The J-valve implantation was successful in both cases. One patient had slight valve displacement when the transporter was withdrawn during the operation, and a second J-valve was implanted in an ideal position. There was no death, no delayed valve displacement, and no readmission during the follow-up period of 12 months. In both cases, there was an absence of trace tricuspid regurgitation. After 6 months of anticoagulation with warfarin, the patients were converted to long-term aspirin treatment.
UNASSIGNED: The ViV technique with J-valve is feasible and effective in treating tricuspid bioprosthetic SVD in high-risk patients, avoiding cardiopulmonary bypass and conventional thoracotomy injury.
摘要：
■三尖瓣生物假体结构瓣膜变性（SVD）患者常表现为右心室扩大和严重功能障碍，导致重做心脏手术的风险更高。2019年，我们的中心创新使用J型瓣膜系统进行瓣膜-瓣膜（ViV）植入治疗三尖瓣生物假体SVD。目的总结随访1年后的临床疗效。
■从2019年4月至2019年10月，用J瓣系统治疗了两例三尖瓣生物假体功能障碍。两个病人都是男性,46岁和67岁，分别。术前评估显示，常规重做心脏直视手术的风险较高。两种情况下的J瓣植入均成功。一名患者在手术过程中取出转运器时瓣膜轻微移位，在理想位置植入了第二个J型瓣膜.没有死亡,无延迟阀门位移,在12个月的随访期内没有再入院。在这两种情况下，没有微量三尖瓣返流。华法林抗凝6个月后，患者转为长期阿司匹林治疗.
■使用J型瓣膜的ViV技术治疗高危患者的三尖瓣生物假体SVD是可行和有效的，避免体外循环和传统开胸手术损伤。
■从2019年4月至2019年10月，用J瓣系统治疗了两例三尖瓣生物假体功能障碍。两个病人都是男性,46岁和67岁，分别。术前评估显示，常规重做心脏直视手术的风险较高。两种情况下的J瓣植入均成功。一名患者在手术过程中取出转运器时瓣膜轻微移位，在理想位置植入了第二个J型瓣膜.没有死亡,无延迟阀门位移,在12个月的随访期内没有再入院。在这两种情况下，没有微量三尖瓣返流。华法林抗凝6个月后，患者转为长期阿司匹林治疗.
■使用J型瓣膜的ViV技术治疗高危患者的三尖瓣生物假体SVD是可行和有效的，避免体外循环和传统开胸手术损伤。
